The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib), ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in EU to treat adult patients with previously untreated mantle cell lymphoma: Cambridge, UK Wednesday, May 7, 2025, 09:0 ...

Shares of AstraZeneca (AZN) rose 1% on Tuesday morning after it announced that its Calquence (acalabrutinib) in combination ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved ...

UK pharma major AstraZeneca (LSE: AZN) today revealed that its Calquence (acalabrutinib) in combination with bendamustine and ...

European stocks were broadly lower on Tuesday as investors assessed the latest batch of earnings and awaited upcoming Fed and BoE meetings. The euro was marginally ...

(Alliance News) - AstraZeneca PLC on Tuesday said Calquence plus chemoimmunotherapy has been approved in the European Union for previously untreated mantle cell lymphoma in adults.

Stocks were edging higher in early trading with market commentary focusing on recent softness in the Greenback against its ...

Meanwhile, US stocks closed lower on Monday, as new figures from EY-Parthenon showed half of all company profit warnings in April flagged a hit from the mounting global trade war amid the fallout from ...

London open The FTSE 100 is expected to open flat on Tuesday, having closed up 1.17% before the long weekend on Friday at 8,596.35.

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).